The aim of this review is to propose the updated diagnostic criteria of epilepsy with myoclonic-atonic seizures (EMAS), which is a recent subject of genetic studies. Although EMAS has been well known as Doose syndrome, it is often difficult to diagnose due to a lack of consensus regarding some of the inclusion criteria. Along with progress in molecular genetic study on the syndrome, it becomes important to recruit electroclinical homogeneous EMAS patients, hence the validity of the clinical criteria should be verified based on recent clinical researches. At present, the most updated ILAE diagnostic manual of EMAS includes: (1) normal development and cognition before the onset of epilepsy; (2) onset of epilepsy between 6 months and 6 years of age (peak: 2-4 years); (3) myoclonic-atonic seizures (MAS) are mandatory (4) presence of generalized spike-wave discharges at 2-3 Hz without persistent focal spike discharges; and (5) exclusion of other myoclonic epilepsy syndromes. In the criteria, we should emphasize that the age at onset of MAS is between 2-5 years in (2), presence of myoclonic-atonic, atonic or myoclonic-flexor seizures (MASs) causing drop attacks associated with generalized spike-wave discharges is mandatory in (3), and epileptic spasms causing drop attacks must be excluded in (5). In the modified criteria, I propose that EMAS is redesignated as genetic generalized epilepsy with MASs, consistent with the familial genetic study conducted by Doose and the recent identification of candidate genes. It should also be noted that EMASs evolves to transient or long-lasting epileptic encephalopathy.
Keywords: Diagnostic criteria; Doose syndrome; Epilepsy with myoclonic-atonic seizures; Genetic heterogeneity; Myoclonic-atonic seizures.
Copyright © 2021 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
Declaration of competing interest There are no conflicts of interest related to this manuscript.
Pittau F, Korff CM, Nordli DR Jr. Pittau F, et al. Epileptic Disord. 2016 Sep 1;18(3):289-96. doi: 10.1684/epd.2016.0854. Epileptic Disord. 2016. PMID: 27506632
Oguni H, Fukuyama Y, Tanaka T, Hayashi K, Funatsuka M, Sakauchi M, Shirakawa S, Osawa M. Oguni H, et al. Brain Dev. 2001 Nov;23(7):757-64. doi: 10.1016/s0387-7604(01)00281-9. Brain Dev. 2001. PMID: 11701290 Review.
Oguni H, Hirano Y, Ito S, Nishikawa A, Otani Y, Nagata S. Oguni H, et al. Epileptic Disord. 2021 Oct 1;23(5):706-712. doi: 10.1684/epd.2021.1316. Epileptic Disord. 2021. PMID: 34519643
Nickels K, Thibert R, Rau S, Demarest S, Wirrell E, Kossoff EH, Joshi C, Nangia S, Shellhaas R; Pediatric Epilepsy Research Consortium. Nickels K, et al. Epilepsy Res. 2018 Aug;144:14-19. doi: 10.1016/j.eplepsyres.2018.04.010. Epub 2018 Apr 25. Epilepsy Res. 2018. PMID: 29729532
Tang S, Pal DK. Tang S, et al. Epilepsia. 2012 Aug;53(8):1303-13. doi: 10.1111/j.1528-1167.2012.03581.x. Epub 2012 Jul 10. Epilepsia. 2012. PMID: 22780699 Review.